Trials / Completed
CompletedNCT03904576
A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms
A Double-blind, Randomised, Two-way Cross-over, Single-dose, Placebo-controlled Trial to Investigate the Effects of BI 1358894 on Cholecystokinin Tetrapeptide (CCK-4) Induced Panic Symptoms in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate the pharmacodynamic effects of a single dose of BI 1358894 on CCK-4- induced anxiogenic/ panic-like symptoms using the PSS in preselected CCK-4 sensitive healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1358894 | Film-coated tablet |
| DRUG | Placebo | Film-coated tablet |
Timeline
- Start date
- 2019-04-18
- Primary completion
- 2019-08-29
- Completion
- 2019-08-29
- First posted
- 2019-04-05
- Last updated
- 2025-03-19
- Results posted
- 2025-03-19
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03904576. Inclusion in this directory is not an endorsement.